(Q36459767)

English

Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group (English)

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

J G Kim

1

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

S K Sohn

2

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Y S Chae

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

H S Song

4

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

K-Y Kwon

5

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Y R Do

6

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

M K Kim

7

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

K H Lee

8

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

M S Hyun

9

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

H M Ryoo

10

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

S H Bae

11

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

K U Park

12

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

W S Lee

13

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

J H Baek

14

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

H Y Chung

15

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

W Yu

16

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

language of work or name

0 references

publication date

22 January 2008

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

98

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

3

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

542-546

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

Oxaliplatin with biweekly low dose leucovorin and bolus and continuous infusion of 5-fluorouracil (modified FOLFOX 4) as a salvage therapy for patients with advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

30 September 2017

Docetaxel and oxaliplatin in the second-line treatment of platinum-sensitive recurrent ovarian cancer: a phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

30 September 2017

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

30 September 2017

Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

30 September 2017

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

30 September 2017

A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

30 September 2017

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

30 September 2017

Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

30 September 2017

A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

30 September 2017

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

30 September 2017

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

30 September 2017

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

30 September 2017

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

30 September 2017

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

30 September 2017

The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

30 September 2017

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

30 September 2017

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

30 September 2017

Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

30 September 2017

Role of carrier ligand in platinum resistance of human carcinoma cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

28 June 2018

Initial or delayed chemotherapy with best supportive care in advanced gastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

28 June 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

28 June 2018

Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

21 September 2018

Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

21 September 2018

Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2243148

21 September 2018

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18212754

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines

1 reference

https://pubmed.ncbi.nlm.nih.gov/18212754

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I study of oxaliplatin in patients with advanced cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18212754

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Oxaliplatin-induced damage of cellular DNA

1 reference

https://pubmed.ncbi.nlm.nih.gov/18212754

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hand-foot syndrome after dose-dense adjuvant chemotherapy for breast cancer: a case series

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604188

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BJC.6604188

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

14 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36459767&oldid=2198923527"